본문 바로가기
KERD
논문KCI 등재

Imipenem 내성 Acinetobacter baumannii에서 항균제 병합요법의 시험관내 상승작용 검사

In vitro Antimicrobial Synergy against Imipenem-Resistant Acinetobacter baumannii

0

조회

0

다운로드

5

인용

0

참고문헌

주제분류병리학

초록

목적 : Imipenem 내성 Acinetobacter baumannii (IRAB)는다른 항균제에도 내성을 지닌 경우가 많아서 기존의 항균제 중에는 효과적인 약제를 찾을 수 없는 경우가 대부분이다. 본 연구에서는 시간-살균 검사를 이용하여 IRAB에 유용한 항균제 병합을찾고 이중디스크확산법 검사로 시간-살균 검사의 결과를 예측할수 있는지를 알아보고자 하였다.재 료 및 방 법 : 1999년 8월부터 2000년 11월까지 본원에서 5명의 환자에서 분리된 IRAB 균주를 대상으로 하였다. Amikacin,gentamicin, tobramycin, piperacillin, piperacillin/tazobactam,cefotaxime, cefepime, cefoperazone/sulbactam (C/S), imipen-em, meropenem, ciprofloxacin, levofloxacin, trimethoprim/famethoxazole, chloramphenicol, minocycline, colistin 등에 대해 한천희석법에 의한 최소억제농도검사를 실시하였다. 항균제감수성 양상별로 3균주를 선별하여 이중디스크확산법에서 상승작용을 보이는 항균제 조합으로 시간-살균 검사를 시행하였다. 결과 : Colistin에 50균주(90.9%), C/S에 50균주, minocycline에 44균주(80.0%)가 감수성이었다. 다른 항균제에 대해서는 20%미만의 감수성을 보였다. 감수성이 있는 항균제를 조합하여 Mino-cycline-imipenem, minocycline-C/S, minocycline-amikacin,imipenem-tobramycin, C/S-amikacin, C/S-tobramycin 등의이중디스크확산법에서 상승작용을 보이면, 시간-살균 검사에서도상승작용을 관찰할 수 있었다. C/S-imipenem 조합은 이중디스크확산법에서는 상승작용을 보였지만 시간-살균 검사에서는 상승작용을 관찰할 수 없었다.

참고문헌 (32)

  1. "Worldwide emergence of car-bapenem-resistant Acinetobacterspp", 41, pp.576~577 (1998)
  2. "In vitro activities of nontraditional antimicrobialsagainst multiresistant Acinetobacter baumannii strains isolated inan intensive care unit outbreak", 44, pp.1035~1040 (2000)
  3. "Antibiotic resistance among clinical isolates of Acinetobac-terin the UK, and in vitro evaluation of tigecycline (GAR-936)", 49, pp.479~487 (2002)
  4. "Prevalenceof class A extended-spectrum -lactamases in clinical isolates ofAcinetobacter baumanniiand Pseudomonas aeruginosa", 26, pp.14~20 (2006)
  5. "Treatment of multidrug resistantAcinetobacter", 18, pp.502~506 (2005)
  6. "Evaluation of methods for detection of anti-microbial resistance of Acinetobacter baumanniito imipenem", 23, pp.388~394 (2003)
  7. "Antimicro-bial resistance surveillance of bacteria in 1999 in Korea with a spe-cial reference to resistance of enterococci to vancomycin and gram-negative bacilli to third generation cephalosporin, imipenem, andfluoroquinolone", 16, pp.262~270 (2001)
  8. "An-timicrobial resistance of clinically important bacteria isolated fromhospitals located in representative provinces of Korea", 6, pp.29~36 (2003)
  9. "Methodsfor dilution antimicrobial susceptibility tests for bacteria that growaerobically; approved standard-sixth edition, M7-A6" (2003), Wayne, Pa:National Committee for Clinical Laboratory Standards
  10. "Performancestandards for antimicrobial susceptibility testing; thirteen informa-tional supplement, M100-S13 (M7)" (2003), Wanye, Pa: National Commit-tee for Clinical Laboratory Standards
  11. "Performancestandards for antimicrobial disk susceptibility tests; approved stan-dard-eighth edition, M2-A8" (2003), Wayne, Pa: National Committee forClinical Laboratory Standards
  12. "Evaluation of antibi-oticsynergy against Acinetobacter baumannii: a comparison with Etest,time-kill, and checkerboard methods", 38, pp.43~50 (2000)
  13. "Colistin: the revival of polymyxinsIRAB에 대한 항균제 상승 작용 117for the management of multidrug-resistant gram-negative bacterialinfections", 40, pp.1333~1341 (2005)
  14. "The use ofintravenous and aerosolized polymyxins for the treatment of infec-tions in critically ill patients: a review of the recent literature", 4, pp.138~146 (2006)
  15. "Useof parenteral colistin for the treatment of serious infection due toantimicrobial-resistant Pseudomonas aeruginosa", 37, pp.154~160 (2003)
  16. "Intravenous colistin in the treatmentof sepsis from multiresistant Gram-negative bacilli in critically illpatients", 7, pp.R78~R83 (2003)
  17. "Intravenous colistin as therapy for nosocomial infections causedby multidrug-resistant Pseudomonas aeruginosaand Acinetobacter bau-mannii", 28, pp.1008~1011 (1999)
  18. "Treatment of multidrug-resistant Acinetobacter baumanniiventilator-associated pneumonia (VAP) with intravenous colistin: a compari-son with imipenem-susceptible VAP", 36, pp.1111~1118 (2003)
  19. "Combination therapy with intravenous colistinfor management of infections due to multidrug-resistant Gram-neg-ative bacteria in patients without cystic fibrosis", 49, pp.3136~3146 (2005)
  20. "Colistin treatment in patients with ICU-acquired infectionscaused by multiresistant Gram-negative bacteria: the renaissanceof an old antibiotic", 11, pp.115~121 (2005)
  21. "Polymyxin-resistant Acinetobacterspp. isolates: what is next?", 9, pp.1025~1027 (2003)
  22. "Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains ofAcinetobacter baumannii: molecular basis for the differential mecha-nisms of action", 50, pp.1251~1256 (2006)
  23. "Com-parison of antimicrobial resistance among subgroups of Acinetobac-ter baumannii", 38, pp.323~ (2006)
  24. "Tetracy-clines for treating multidrug-resistant Acinetobacter baumannii ven-tilator-associated pneumonia", 29, pp.2072~2076 (2003)
  25. "Effect of sulbactam on infections caused by imipenem-resistant Acine-tobacter calcoaceticusbiotype anitratus", 167, pp.448~451 (1993)
  26. "In-vitro and in-vivo activities of sulbactamand YTR830H against Acinetobacter calcoaceticus", pp.677~82
  27. "In vivo efficacies ofcombinations of beta-lactams, beta-lactamase inhibitors, and rifampinagainst Acinetobacter baumanniiin a mouse pneumonia model", 43, pp.1406~1411 (1999)
  28. "Com-parison of efficacy of efoperazone", sulbactam and imipenem, pp.2006, 47[DOI]
  29. "Treatment of multidrug-resistantAcinetobacter baumanniimeningitis with ampicillin", sulbactam, 1997, pp.24, 932~935
  30. "Antimicrobial combinations", pp.365~440 (2005), Philadel-phia: Lippincott Williams & Wilkins
  31. "In vitro activity of antimicrobial combina-tion against multidrug-resistant strains of Acinetobacter baumannii", 10, pp.1098~1101 (2004)
  32. "In vitro synergy test of meropenem and sulbactam against clinicalisolates of Acinetobacter baumannii", 52, pp.317~322 (2005)

관련 논문AI추천

이 간행물의 다른 논문 (6건)